Biomarker Testing with Next-Generation Sequencing Guides Targeted Therapies in Non-Small Cell Lung Cancer Treatment

Biomarker testing is changing the landscape of non-small cell lung cancer (NSCLC) treatment. These tests inform the use of targeted therapies and next-generation sequencing, offering the potential for improved patient care. Specifically, biomarker testing guides doctors in selecting the most appropriate targeted therapies for individual NSCLC patients. This testing involves next-generation sequencing, a comprehensive method for analyzing a patient’s tumor. By identifying specific biomarkers, physicians can tailor treatment plans to the unique characteristics of each patient’s cancer. These advances contribute to better outcomes in the treatment of non-small cell lung cancer.

Newsflash | Powered by GeneOnline AI
Date: April 30, 2025

Author

Mark Chiang